eligibility_summary
Eligible: adults ≥18 with R/R large B-cell lymphoma (DLBCL/tFL/PMBCL), measurable FDG-avid disease, ECOG 0-1, clinically stable, no active CNS dz, CAR-T-eligible after ≥2 prior lines incl anti-CD20 + anthracycline, not pregnant, contraception, therapy washouts. Exclude: bulky ≥10 cm, <2 lines, prior CD19/CAR-T/allo-SCT, other cancer <3 y, uncontrolled infection (HBV/HCV/HIV/TB), CNS/cardiac/pulmonary/autoimmune dz, recent DVT/PE/live vaccine, indwelling drains, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b ODIN trial in R/R DLBCL receiving standard‑of‑care axicabtagene ciloleucel (Yescarta, autologous anti‑CD19 CAR‑T cell therapy). Interventions tested: lymphodepletion with fludarabine 30 mg/m2 (purine nucleoside analog antimetabolite, inhibits DNA synthesis, lymphotoxic) plus cyclophosphamide 500 vs 750 mg/m2 (alkylating chemotherapy, DNA crosslinking, lymphodepletion), with or without total lymphoid irradiation (TLI 2 Gy ×2, targeted radiation to deplete lymphoid tissues). Mechanistic goal: deepen lymphodepletion to enhance CAR‑T expansion/persistence by reducing competing/suppressive host lymphocytes and increasing homeostatic cytokines (IL‑7/IL‑15). Targets: CD19+ malignant B cells (CAR‑T), host T/B/NK cells and lymphoid compartments (Flu/Cy/TLI), DNA damage/replication pathways.